Market Pulse Archives

July 12, 2021, 3:36 p.m. EDT

J&J's COVID-19 shot may be connected to rare autoimmune disorder: report

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Johnson & Johnson (JNJ)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Johnson & Johnson /zigman2/quotes/201724570/composite JNJ +0.37% were down 0.2% on Monday after the Washington Post reported that U.S. regulators plan to issue a new safety warning for the company's COVID-19 shot. The adenovirus viral vector, single-shot vaccine may be tied to rare instances of Guillain-Barré syndrome. The Post, citing data from the Centers for Disease Control and Prevention, reported that there have been 100 cases of the autoimmune disorder among the roughly 12.6 million people who have received the J&J shot. The vaccine, which received emergency authorization in February, has struggled to gain its footing among Americans after manufacturing issues at a plant in Maryland and a confirmed association with ultra-rare blood clots. J&J's stock is up 7.7% so far this year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX +0.99% has gained 16.3%.

/zigman2/quotes/201724570/composite
US : U.S.: NYSE
$ 167.20
+0.62 +0.37%
Volume: 633,408
Jan. 20, 2022 10:14a
P/E Ratio
24.99
Dividend Yield
2.54%
Market Cap
$439.91 billion
Rev. per Employee
$679,695
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,577.52
+44.76 +0.99%
Volume: 423.23M
Jan. 20, 2022 10:14a
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.